These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25766958)

  • 1. Reply: considerations for drug development for heart failure.
    Greene SJ; Gheorghiade M
    J Am Coll Cardiol; 2015 Mar; 65(10):1061-2. PubMed ID: 25766958
    [No Abstract]   [Full Text] [Related]  

  • 2. Considerations for drug development for heart failure.
    Ghali JK
    J Am Coll Cardiol; 2015 Mar; 65(10):1060-1. PubMed ID: 25766957
    [No Abstract]   [Full Text] [Related]  

  • 3. Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure.
    Greene SJ; Gheorghiade M
    J Am Coll Cardiol; 2014 Oct; 64(15):1599-601. PubMed ID: 25301464
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply: Mode of Death Prevention by Serelaxin.
    Felker GM; Metra M; Teerlink JR
    J Am Coll Cardiol; 2015 Jul; 66(1):99. PubMed ID: 26139069
    [No Abstract]   [Full Text] [Related]  

  • 5. Mode of Death Prevention by Serelaxin.
    Henry BL; Schwartzman DS; Salama G
    J Am Coll Cardiol; 2015 Jul; 66(1):98-9. PubMed ID: 26139068
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
    Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
    J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
    Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
    Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First clinical experience with intravenous recombinant human relaxin in compensated heart failure.
    Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
    Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising news about heart failure. Novel drug improves breathing and appears to extend life.
    Harv Heart Lett; 2013 Apr; 23(8):6. PubMed ID: 23914394
    [No Abstract]   [Full Text] [Related]  

  • 10. Relaxin: a new approach for the treatment of acute congestive heart failure.
    Grossman J; Frishman WH
    Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical inquiries. Do antiarrhythmics prevent sudden death in patients with heart failure?
    Ball TA; Kerns JW; Nashelsky J; Saseen J
    J Fam Pract; 2003 Sep; 52(9):719-21. PubMed ID: 12967547
    [No Abstract]   [Full Text] [Related]  

  • 12. Relaxing from dyspnoea.
    Swedberg K
    Eur Heart J; 2014 Apr; 35(16):1017-8. PubMed ID: 24459195
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of the RELAXin in acute heart failure study.
    Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
    Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RELAX-AHF: consistency across subgroups and new hypotheses generated.
    Schmieder RE
    Eur Heart J; 2013 Oct; 34(40):3100-1. PubMed ID: 23999455
    [No Abstract]   [Full Text] [Related]  

  • 15. Sudden cardiac death--the challenge to cardiology.
    Kjeldsen K; Atar D; Hallén J; Vardas P; Zannad F; Haunsø S
    Fundam Clin Pharmacol; 2010 Oct; 24(5):535-7. PubMed ID: 20854303
    [No Abstract]   [Full Text] [Related]  

  • 16. Sudden cardiac death after heart failure; symptomatic versus disease treatment? An editorial comment.
    Buckberg GD;
    Heart Fail Rev; 2004 Oct; 9(4):347-51. PubMed ID: 15886980
    [No Abstract]   [Full Text] [Related]  

  • 17. Sudden death in CHF.
    Sørensen HT
    Am Heart J; 1991 Dec; 122(6):1792. PubMed ID: 1957783
    [No Abstract]   [Full Text] [Related]  

  • 18. Interrelationship of magnesium and congestive heart failure.
    Seelig MS
    Wien Med Wochenschr; 2000; 150(15-16):335-41. PubMed ID: 11105329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of beta-blockers in preventing sudden death in heart failure.
    Teerlink JR; Massie BM
    J Card Fail; 2000 Jun; 6(2 Suppl 1):25-33. PubMed ID: 10908095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traditional heart failure medications and sudden cardiac death prevention: a review.
    Al Chekakie MO
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):412-26. PubMed ID: 23766358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.